Chairs: Carl-Wilhelm Vogel, Hector A. Cabrera-Fuentes

3x15 min talk, 15 min QA

• 1.1 Derek Hausenloy (Singapore)
  Challenges and opportunities with cardioprotection
• 1.2 Sven Reischauer (Giessen, Germany)
  Heart regeneration in zebrafish
• 1.3 Devrim Gözüaçık (Istanbul, Turkey)
  Autophagy in health and disease

Chairs: Sandrine Lecour, Indrajit Banerjee

4x15 min talks, 15 min QA

• 2.1 Elisa Liehn (Singapore)
  Phospholipids in cardiovascular diseases
• 2.2 Jürgen Bernhagen (Munich, Germany)
  Role of new MIF proteins in cardiovascular disease
• 2.3 Stefano Romeo (Gothenburg, Sweden)
  Human and molecular genetics of steatotic liver disease
• 2.4 Marianne Benn (Copenhagen, Denmark)
  Obesity and cardiovascular disease risk

Chairs: Dilek Ural, Devrim Gözüaçık

4x15 min talks, 15 min QA

• 3.1 Peter Ferdinandy (Budapest, Hungary)
  Discovery and development of miRNA therapeutics for cardioprotection and other indications
• 3.2 Ender Ödemiş (Istanbul, Turkey)
  Three dimensional modelling and simulations in the treatment of congenital heart disease
• 3.3 Klaus T. Preissner (Giessen, Germany)
  Targeting cardiovascular diseases with endonucleases
• 3.4 Kemal Baysal (Istanbul, Turkey)
  An in vitro co-culture model to study exosomes in vascular cell communication

Chairs: Marianne Benn, Sven Reischauer

4x15 min talks, 15 min QA

• 3.5 Hector A. Cabrera-Fuentes (Hamburg, Germany)
  Mitochondrial fission regulator Drp-1 as a novel therapeutic target to prevent atherosclerosis
• 3.6 Thomas Krieg (Cambridge, UK)
  Clinical development of acidic malonate in ischemia-reperfusion Injury
• 3.7 Müjdat Zeybel (Istanbul, Turkey)
  Integrative proteo-transcriptomic characterization of advanced fibrosis in chronic liver disease across etiologies
• 3.8 Indrajit Banerjee (SSR College, Mauritius)
  Cardiac complications due to COVID-19 vaccines

Chairs: Peter Ferdinandy, Kemal Baysal

5x15 min talks, 15 min QA

• 4.1 Sandrine Lecour (Cape Town, South Africa)
  High density lipoprotein particles and cardioprotection: where do we stand?
• 4.2 Roshni R. Singaraja (Singapore)
  2-deoxyuridine associates with recurrent coronary events
• 4.3 Lale Tokgözoğlu (Istanbul, Turkey)
  Atherosclerotic vascular disease and LDL-cholesterol : Why is lower better?
• 4.4 Zsuzsanna Helyes (Pécs, Hungary)
  Mitochondrial uncoupling protein 2 mediates inflammatory cardio-pulmonary dysfunctions: in vivo rat studies
• 4.5 Belma Turan (Istanbul, Turkey)
  Contribution of electrotonic conduction by non-myocytes to cardiomyocyte electrical activity in insulin-resistant hearts

Chairs: Ece Yurtseven, Klaus T. Preissner, Derek Hausenloy

5x8 min talks, 20 min QA

• 5.1 Dila Atak
  Pericytes Play A Protective Role During Neuroinflammation
• 5.2 Shaghayegh Soleimani
  The Impact of Epigenetic Modifications of GCKR on Metabolic Associated Steatotic Liver Disease (MASLD)
• 5.3 Pınar Cevikbaş Ilik
  Magnolia Officinalis provides cardioprotection from myocardial damage by modulating mitochondria function
• 5.4 Eda Nur Saruhan
  Comparative Analysis of Fiber Orientation and Density in Commercial Porcine and Native Human Heart Valves: Implications for Clinical Use
• 5.5 Hande Uludağ
  The Use of Cell-Free DNA Methylation as a Biomarker for Fibrosis: Data from MASLD Patients

Chairs: Kemal Baysal, Jürgen Bernhagen

6x15 min talks, 2x10 min QA

• 6.1 Chrishan Ramachandra (Singapore)
  Myeloperoxidase - a key mediator in the pathogenesis of heart failure with preserved ejection fraction (HFpEF)
• 6.2 Meral Kayıkçıoğlu (Istanbul, Turkey)
  Clinical studies in familial hypercholesterolaemia
• 6.3 Manvendra Singh (Singapore)
  Semaphorin-plexin-neuropilin signaling and left ventricular non-compaction (LVNC)

Chairs: Kemal Baysal, Jürgen Bernhagen

6x15 min talks, 2x10 min QA

• 6.4 Özlem Yalçın (Istanbul, Turkey)
  Blood mechanical damage: Pathophysiology and clinical consequences
• 6.5 Jiong-Wei Wang (Singapore)
  Promise of milk-derived extracellular vesicles in cardiometabolic diseases
• 6.6 Paul Yen (Singapore)
  Metabolic dysfunction-associated steatohepatitis has a direct role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF)

• Announcement: 9th Meeting “New Frontiers in Cardiovascular Research” in ...........
  Myeloperoxidase - a key mediator in the pathogenesis of heart failure with preserved ejection fraction (HFpEF)
• Prize Giving (top 3 posters and best young investigator presentation)
  Clinical studies in familial hypercholesterolaemia
• Concluding remarks
  • Derek J. Hausenloy (Singapore)
  • Klaus T. Preissner (Giessen, Germany)
  • Ece Yurtseven (Istanbul, Turkey)